Core Viewpoint - The release of the "China Clinical Smoking Cessation Expert Consensus Gold Standard (2025 Update)" aims to provide clear guidelines for doctors and patients in smoking cessation and control, emphasizing the importance of smoking cessation as a public health intervention [1][6] Group 1: Expert Consensus Content - The updated consensus identifies varenicline tartrate as a first-line medication for smoking cessation, supported by clinical studies showing its effectiveness in reducing cravings and withdrawal symptoms [2] - The consensus also includes other first-line adjunctive medications such as nicotine replacement therapy and bupropion, advocating for a combined approach of medication and behavioral support [2] - Non-pharmacological strategies recommended include the 5A model (Ask, Advise, Assess, Assist, Arrange) and various support measures like counseling, specialized clinics, hotlines, and apps [2] Group 2: Introduction of "Smoking Control" Concept - The consensus introduces a phased intervention approach distinguishing between smoking control and cessation, targeting individuals who are not ready to quit but willing to reduce their smoking [3] - This phased model aims to help smokers gradually decrease their consumption and enhance their willingness to quit, ultimately leading to complete cessation [3] Group 3: Corporate Responsibility and Collaboration - Varenicline tartrate is positioned as a key tool for clinicians to enhance the success rates of smoking cessation efforts [4] - The company, Hangzhou Minsheng Health Pharmaceutical, aims to integrate smoking control with public welfare initiatives, marking its centennial in 2026 as a commitment to national health [4] - The long-term advocacy by experts like Academician Hu Dayi has established a strong foundation for the credibility of the new smoking control standards, promoting ongoing public health efforts [5] Group 4: Implementation and Future Directions - The consensus provides actionable smoking cessation strategies for clinicians and smokers, transitioning from theoretical research to clinical practice [6] - The integration of smoking cessation into chronic disease management requires collaboration across policy, academia, industry, and society, marking a new phase in China's smoking control efforts [6]